Colorectal Cancer

CDC researchers said they did not find a recent increase in cases of hepatitis or adenovirus types 40/41 among children in the United States compared with pre-pandemic baseline levels.

Men, older patients and patients with low income were among those with elevated risk for CVD hospitalization prior to receiving a diagnosis of potentially curable cancer, researchers reported.

In this video, Michael Cecchini, MD, discussed the late-breaking phase 3 PARADIGM trial presented at an ASCO Annual Meeting plenary session.

In this video, Christine M. Walko, PharmD, BCOP, FCCP, discussed four colorectal cancer presentations from ASCO Annual Meeting, including the phase 3 TRIPLETE study, phase 3 STRATEGIC-1 study, IMPROVE study and late-breaking PARADIGM trial.

In this video, Christine M. Walko, PharmD, BCOP, FCCP, discussed the importance of biomarker testing and the challenges involved.

In a meta-analysis of triluridine/tipiracil (TAS-102) plus bevacizumab triluridine/tipiracil alone, there was a benefit to adding bevacizumab for patients with lateline colorectal cancer that is metastatic.

In this video, Howard S. Hochster, MD, FACP, discusses a late-breaking abstract on the phase 3 PARADIGM trial, which looked at panitumumab vs. bevacizumab as first-line treatment in patients with RAS wild-type metastatic colorectal cancer.

The AGA has released a series of evidence-based position statements that support a nationwide colorectal cancer screening approach and aim to eliminate current barriers in the screening process.

In a Healio video exclusive, Chris Evans, president of the Colon Cancer Coalition and Healio’s 2021 Patient Voice Disruptive Innovator, shares updates on the organization’s recent accomplishments and future plans.

Angela M. Nicholas, MD, says that no patient she sees aged older than 45 years leaves her office without discussing cancer screening.